Vyome Holdings, Inc. (NASDAQ:HIND) Given Average Recommendation of “Hold” by Brokerages

Vyome Holdings, Inc. (NASDAQ:HIND) has been assigned a consensus rating of “Hold” from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $15.00.

Several equities analysts have weighed in on HIND shares. Weiss Ratings raised Vyome from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Litchfield Hills Research started coverage on shares of Vyome in a research report on Monday, May 4th. They issued a “buy” rating on the stock. Finally, Zacks Research raised Vyome to a “hold” rating in a research note on Wednesday, May 6th.

Institutional Trading of Vyome

A hedge fund recently bought a new stake in Vyome stock. Geode Capital Management LLC bought a new position in shares of Vyome Holdings, Inc. (NASDAQ:HIND) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned 0.21% of Vyome at the end of the most recent reporting period. Institutional investors and hedge funds own 22.06% of the company’s stock.

Vyome Stock Performance

Shares of NASDAQ HIND opened at $2.30 on Friday. The firm has a market cap of $16.14 million, a P/E ratio of -0.19 and a beta of 1.49. The business’s 50 day moving average is $2.16 and its 200-day moving average is $2.57. Vyome has a 1-year low of $1.75 and a 1-year high of $18.60.

Vyome (NASDAQ:HIND) last posted its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter. The firm had revenue of $0.03 million during the quarter. Analysts forecast that Vyome will post -0.6 EPS for the current year.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.